PETN DESI hearing
Executive Summary
PETN DESI hearing: Began Oct. 5 and is scheduled to run through Oct. 25 in room 4-35-A at FDA's Parklawn Building in Rockville, Maryland. Witnesses that will be cross-examined include representatives from Warner-Lambert and Bolar, as well as FDAers and outside experts representing the agency. In 1984, FDA proposed to withdraw the NARDs for single-entity coronary vasodilators containing pentaerythritol tetranitrate, citing the lack of the products efficacy for treating angina.